Remix Therapeutics Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Watertown MA US

Primary Industry

Biotechnology

About

Founded in 2018 and based in Massachusetts, US, Remix Therapeutics Inc. operates as a biotechnology research company that reprograms RNA processing and designs therapeutic drugs for treating diseases of high unmet medical need. In January 2024, Remix Therapeutics Inc. raised USD 60 million in series B funding led by returning investor The Column Group, with participation from other investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, etc. The firm as of July 2024, is led by its co-founder, President, and CEO, Pete Smith, and Dominic Reynolds (Chief Scientific Officer), and Chris Bowden (Chief Medical Officer). Remix Therapeutics specializes in - RNA Modulation: utilizing REMaster™ to discover and develop small molecules that modulate RNA processing; and Drug Discovery: advancing novel therapies targeting disease-driving mRNA and protein expression. These therapeutics aim to transform patients' lives by influencing the processing of RNA to control disease-driving gene expressions. The company also offers a platform that integrates data science, biology, biomolecular sciences, and medicinal chemistry to identify druggable targets and optimize compounds from a proprietary library. The company plans to utilize the January 2024 funding to support the clinical development of its lead drug candidate REM-422 and further advancement of its pipeline of RNA-processing targeted therapeutics.

Current Investors

ARCH Venture Partners, Atlas Venture, Alexandria Venture Investments

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.remixtx.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.